How Saudi Arabia Will Manage the Oil Market in 2017

Robert Boslego - INO.com Contributor - Energies


OPEC agreed in Algeria to limit future oil production. This represents a major shift in the policy announced in November 2014 to compete for market share through lower prices.

The OPEC communique stated the group will retain output to a "target range of 32.5 to 33.0 million barrels per day" (mmbd). In the latest OPEC Monthly Oil Market Report (MOMR), OPEC reported that production average 33.4 mmbd in September. While that is not far above the target range, there are other problems looming on the horizon; several countries—Nigeria, Iran, Iraq, and Libya—all want to restore their output to levels they were at before their supplies were disrupted, and that could push OPEC’s output up to nearly 35 mmbd if they succeed.

Saudi Energy Minister Khalid Al-Falih reversed KSA’s position from last April when it would not freeze output without Iran’s agreement to do the same. Instead, he said, Iran, Nigeria and Libya would be allowed to produce "at maximum levels that make sense as part of any output limits which could be set as early as the next OPEC meeting in November."

My interpretation is that Saudi Arabia and the smaller Gulf producers are therefore going to have to absorb the cuts if they intend to achieve the target. Continue reading "How Saudi Arabia Will Manage the Oil Market in 2017"

Weekly Futures Recap With Mike Seery

We've asked Michael Seery of SEERYFUTURES.COM to give our INO readers a weekly recap of the Futures market. He has been Senior Analyst for close to 15 years and has extensive knowledge of all of the commodity and option markets.

Michael frequently appears on multiple business networks including Bloomberg news, Fox Business, CNBC Worldwide, CNN Business, and Bloomberg TV. He is also a guest on First Business, which is a national and internationally syndicated business show.

Cotton Futures

Cotton futures in the December contract is now trading above its 20 and 100-day moving average for the first time since last summer as prices spiked higher off of the USDA crop report stating that ending stocks currently stand at 4.3 million bales and that is down 12% from the September report sending prices to a 2 week high. At present, I’m sitting on the sidelines in this market as there is no trend, but it does look to me that a possible bottom has been created as prices settled last Friday in New York at 66.98. It's currently trading at 69.65 up about 300 points for the trading week despite the fact that the U.S dollar has now hit an 8 month high and a 31 year high against the British Pound which is generally a negative influence on commodity prices. Harvest is in full swing in the southern part of the United States as there were concerns about Hurricane Matthew potentially damaging yields as the next report will state if that situation is true. Continue reading "Weekly Futures Recap With Mike Seery"

Is The Market STRESSING OUT?

Hello MarketClub members everywhere. I believe that the market is stressing out.

That's my take on what's going on right now in the market.

MarketClub's Mid-day Market Report

The Trade Triangles have indicated for seven weeks that the market was in fact in a state of uncertainty. That remains true today just as it did seven weeks ago.

Let's move on; it's Friday and the big winner for the week is Crude Oil which is up 3.54% for the week. The big loser for the week so far is gold which is down 4.86%. Let's examine how the Trade Triangles are positioned on both of these markets. Continue reading "Is The Market STRESSING OUT?"

Preview Issue #4 - Mylan Capitulates, M&A Activity Heats Up and the Negative Political Backdrop

INO Health & Biotech Stock Guide

Preview Issue #3 - October 13th, 2016

BIOTECH, HEALTH & PHARMA NEWS

Mylan has been a whipping post as of late over its aggressive pricing increases regarding its EpiPen which uses an auto-injection of epinephrine to treat severe allergic reactions in primarily school age children. As a result, Mylan has ostensibly capitulated in the face of public and governmental scrutiny regarding its EpiPen pricing with implementing plans to offer a generic version and a $465 million settlement with the U.S. department of Justice to appease the public and improve its company image. The relentless congressional grilling on Capitol Hill and public backlash against Mylan and its CEO looks to have spurred the company into offering a generic and cheaper version of its EpiPen as well as providing more EpiPen via its access programs. However, congressional leaders continue to criticize Mylan over its alleged misrepresentation of profits and under paying Medicare in rebates. Congressional leaders stated that Mylan was dishonest when it incorrectly applied a statutory U.S. tax rate on its EpiPen revenue. The company is technically based ex-U.S. and thus pays a lower tax rate. Furthermore, the company has been accused of misclassifying the EpiPen to game the Medicaid Drug Rebate Program. Mylan has been reportedly paying a 13% rebate that is reserved for generics while the brand name EpiPen should be at a minimum of a 21% rebate rate. Congressional leaders have vowed to recoup the difference over the past five years Medicaid has spent on EpiPens (total Medicaid spending from 2011 through 2015 was reported to be $960 million for the EpiPen). To this end, Mylan just settled a $465 million lawsuit regarding this egregious misclassification under the Medicaid Drug Rebate Program. This negative publicity along with continuous political attacks has been a major overhang impacting biotech stocks. This public and contentious battle with government officials and the general public doesn’t bode well for the entire healthcare cohort. With ongoing presidential debates and political posturing still occurring, this will likely continue to be a source of volatility. Buying opportunities may present themselves throughout the sector due to extraneous political rhetoric regarding the drug pricing debate and the entire drug supply chain dynamics.

WHAT'S NEXT

Continue reading "Preview Issue #4 - Mylan Capitulates, M&A Activity Heats Up and the Negative Political Backdrop"

Gold's Next Big Move

Hello MarketClub members everywhere. Good to be back, I was away visiting family and unfortunately I picked up a really bad cold. I'm sure you had times like this yourself when you just feel lethargic and don't feel like doing anything. Well, that was then and this is now so let's get the show on the road.

MarketClub's Mid-day Market Report

In today's video update, I'm going to be analyzing gold (FOREX:XAUUSDO) and I am going to be share with you something that I noticed that has been 100% accurate this year in gold, I'm sure you'll find it interesting.

Of course, I will be covering the other markets and the choppy action we are seeing in most of the major indices. A great deal of this indecisive market action I believe has to do with the general uncertainty that's pervasive in the US right now. The main culprit is the upcoming presidential election which is less than 30 days away.

I will also be taking a look at Amazon.com (NASDAQ:AMZN) and Apple Inc. (NASDAQ:AAPL). Both the stocks look very interesting particularly as Amazon reentered the music market today. Amazon is tying music subscriptions both to its Prime accounts as well as ECHO its Alexa-driven knowledge machine both could, in fact, catch the imagination of many Amazon Prime ECHO users.

Stay focused and disciplined.

Every success with MarketClub,
Adam Hewison
President, INO.com
Co-Creator, MarketClub